Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
about
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complicationsLp-PLA2 Inhibitors for the Reduction of Cardiovascular EventsAnti-inflammatory therapies for cardiovascular diseaseSTABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialModulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk.Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study.Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.Critical appraisal of inflammatory markers in cardiovascular risk stratification.Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.Unraveling the PAF-AH/Lp-PLA2 controversy.Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China.The effect of Danshen extract on lipoprotein-associated phospholipase A2 levels in patients with stable angina pectoris: study protocol for a randomized controlled trial - the DOLPHIN study.The Prognostic Value of Lipoprotein-Associated Phospholipase A2 in the Long-Term Care of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.Decrease of small dense LDL and lipoprotein-associated phospholipase A2 due to human growth hormone treatment in short children with growth hormone deficiency and small for gestational age status.Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects.Impact of rosuvastatin treatment on reduction of thrombus burden in rat acute inferior vena cava stenosis
P2860
Q26777871-AE84C929-14B2-47DF-B28E-2184D0DC6CB6Q33936097-F54A5A2A-5D76-43EB-8D72-D3B044ABA755Q34137872-F59560B0-3D19-456E-8DCA-697B0B6E2373Q35217973-A4AECFC2-1AA9-4400-A027-545A4A82F641Q36019971-ADF8A83D-AC48-4025-9806-0F35CA260AB7Q36145180-0FD880FC-31A0-4F52-9EF2-388FC7C030F4Q36272238-45F92EB8-F0A5-477A-9DE2-DC4E575829E1Q36752159-2871181F-F1BC-417A-B1B6-0AA249ED79D0Q36811443-639AD819-4B4E-4F97-A5AE-3019B35AF184Q37076194-CA1BB4AD-93D1-4038-9EBD-3C586F457C1DQ37254899-02D48872-C15D-4E80-ACC4-D89D7A36F72CQ37328799-80430D80-2ACB-4AE0-A1B0-E367AE30D8A4Q37380902-4599E317-0357-468D-84CF-2D7637F34A0AQ37604553-59AA517B-E22A-47CE-94A1-EDF5D9F565FCQ37623853-4A30F43D-E9AC-47EC-89D6-21BF06323415Q37671955-BEAB4819-A2D2-4CA4-A2A4-C4EEDD92312BQ38219501-82EAA30C-117E-4D37-AE3D-44D9A0937E22Q38377434-0FD75EF0-6D33-41A1-875F-0DCB27EC039AQ42138491-8C9B398A-49A3-411A-9330-ED5E6FB748F7Q43204699-E5C0E6C7-2B3F-473C-9814-EC1AFA27B45AQ44652488-2E146242-47B8-480A-8F18-01E3234E5BEAQ47137236-5E998DE2-A1A8-43F7-BA6D-DF8EBEFAEFC0Q47164065-DB942C17-1529-49D5-85AA-6A7DC35EE9EAQ50089457-F418847F-A751-4789-A67A-FD2F39EF5765Q53660860-4DAA7E94-977A-4F1C-918C-83CCF0C97F7DQ54006194-E5987B99-9EE3-45A1-9EAA-4C10C440FEFDQ59320912-180C3292-D6E2-4977-AE40-EFA226C11F2D
P2860
Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Relationship of lipoprotein-as ...... alysis from the JUPITER trial.
@en
type
label
Relationship of lipoprotein-as ...... alysis from the JUPITER trial.
@en
prefLabel
Relationship of lipoprotein-as ...... alysis from the JUPITER trial.
@en
P2093
P1433
P1476
Relationship of lipoprotein-as ...... alysis from the JUPITER trial.
@en
P2093
Jean G MacFadyen
Paul M Ridker
Robert L Wolfert
P304
P356
10.1373/CLINCHEM.2011.180281
P407
P577
2012-03-14T00:00:00Z